Sinovac phase 3 trial results

Sinovac phase 3 trial results. 3%) efficacious against HFMD caused by EV71. 1%) of 6646 in the vaccine group and five (0. This is a more conventional vaccine than the mRNA and vector vaccines currently in use in the UK: it uses “killed” SARS-CoV-2 virus as the antigen. This was a double-blind, randomised, placebo-controlled phase 3 trial. Nov 18, 2020 · Researchers say the latest results for CoronaVac support moving forward to Phase 3 trials. CoronaVac was tested on a total of 421 healthy adults aged between 60 to 89 years old in the phase I/II clinical trial. Monday, June 14, 2021. BEIJING, September 25, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. Mar 14, 2013 · The Phase III trial showed good immunogenicity and safety for Sinovac's EV71 vaccine. 4% to 90%. Emergency use in many countries. 1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine. Serum samples were collected before the first dose and 30 days after the third Sep 9, 2020 · The governor of Brazil's São Paulo state said on Wednesday that Phase 3 clinical trials of a potential COVID-19 vaccine developed by China's Sinovac Biotech Ltd have shown promising results and it may be available to Brazilians as early as December. They found the Sinovac vaccine did create an antibody immune response, but at lower levels than those Feb 3, 2021 · Sinovac has never released Phase 3 trial data for independent peer review, and it has been criticized by experts for a lack of transparency. While the Feb 27, 2014 · BEIJING, Feb. ("Sinovac Beijing") on the unblinding conference held on April 19, 2018. 42%, a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its Jan 10, 2012 · The Phase III clinical trial is expected to enroll up to 10,000 healthy volunteers with ages 6-35 months, and was designed as a randomization, double blinded, placebo controlled study. Defne Ozkan at Istanbul's Cerrahpasa Jan 19, 2021 · Data from Sinovac’s Phase 3 trials conducted in Indonesia, Turkey, Brazil, and China have shown 4 different overall efficacy results, ranging from 50. Sep 1, 2021 · Point estimates of vaccine efficacy from phase 3 trials, often with relatively wide and overlapping confidence intervals, vary considerably among vaccine products. Individuals with SARS-CoV-2 exposure or infection history were excluded. Jan 10, 2012 · Sinovac anticipates the trial to be completed in the first half of 2013. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine (“sIPV”) developed by Sinovac Biotech Co. participants have racially and ethnically diverse backgrounds, and 41% of global and 45% of U Jun 13, 2020 · Sinovac Biotech Ltd. 743 participants received at least one dose of the investigational product (143 for phase 1 and 600 Sep 25, 2017 · -- Phase III Preliminary Results Demonstrate Vaccine Efficacy Rate of87. Jun 28, 2021 · We did a double-blind, randomised, controlled, phase 1/2 clinical trial of CoronaVac in healthy children and adolescents aged 3–17 years old at Hebei Provincial Center for Disease Control and Prevention in Zanhuang (Hebei, China). In July 2020, Jul 6, 2020 · On July 3, 2020, the Brazilian National Regulatory Agency, Anvisa, granted approval to a phase III clinical trial sponsored by Instituto Butantan to test efficacy and safety of the inactivated COVID-19 vaccine developed by Sinovac Life Sciences Co. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the unblinding of the Phase I clinical trial results for the adult population for its proprietary inactivated vaccine against human enterovirus 71 (EV71), which causes hand, foot, and mouth disease (HFMD). The investigational vaccine known as mRNA-1273 was 94. A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults. The phase III Nov 20, 2020 · Sinovac may get Phase III trial results of COVID-19 vaccine by December, executive says. Of the total 743 healthy participants aged 18 to 59 years, 143 are in Jul 8, 2021 · CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. Dec 5, 2020 · Sinovac and Sinopharm, China’s two leading vaccine makers, are currently testing three vaccine candidates in phase III trials with candidates that could be distributed without cold storage Mar 25, 2013 · The primary objective of the Phase III trial was to evaluate the efficacy of the EV71 vaccine in the prevention of HFMD caused by EV71 in infants of 6 to 35 months old. The vaccine also demonstrated efficacy in preventing severe COVID-19. 1%) of the 10,214 participants, including six (0. Published clinical trial results indicate that the inactivated EV71 vaccines have good safety and immunogenicity in the target population (infants Dec 16, 2022 · 3 Russell KL, Rupp RE, Morales-Ramirez JO, et al. , co-administration group 1 (group C1), co-administration group 2 (group C2), staggered administration group 1 (group S1) and staggered Sep 23, 2020 · This randomized, double-blinded, and placebo-controlled phase I/II clinical trial among adolescents and children between the ages of 3-17 years old was approved by the Ethics Committee of the Hebei Provincial CDC on September 11, 2020, with the trial expected to commence soon. Among them, at least eight COVID-19 vaccines have been granted emergency use and/or full marketing authorization by the regulatory authorities, namely CoronaVac, HB02 (BBIBP-CorV), AZD1222 (ChAdOx1-S), Sputnik V (Gam-COVID-Vac), Ad26 Jul 8, 2021 · CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. , a leading provider of biopharmaceutical products in China, today announced phase III results. The Phase II trial, completed in November 2011, confirmed favorable safety and tolerance profiles, and good immunogenicity. Phase III results from Turkey published in The Lancet showed an efficacy of 84% based on 10,218 participants in the trials. Apr 5, 2021 · 2. Apr 19, 2018 · BEIJING, April 19, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. Jun 1, 2021 · At least 10 vaccines are in phase III clinical trials, 3 of them have ended phase III with positive results . An overview for year 2006 ~ 2016 indicated the dominant S. 0% against type 1 poliovirus, 94. 4 – 92. (NASDAQ: SVA), a leading provider of vaccines in China, announced today preliminary top-line data from its Phase III Dec 8, 2020 · In Brazil, Sinovac’s Phase III trial has reached an advanced stage; it started in July and includes 13,000 individuals. November 20, 2020 10:32 AM UTC Updated ago FILE PHOTO: A man works in the packaging facility of Jun 10, 2022 · A large phase 3 trial in Brazil showed that two doses, administered at an interval of 14 days, had an efficacy of 51% against symptomatic SARS-CoV-2 infection, 100% against severe COVID-19, and 100% against hospitalization starting 14 days after receiving the second dose. Participants ranged in age from 18 to 59 and were recruited from a single county Jun 15, 2020 · China-based Sinovac Biotech has reported positive preliminary data from the Phase I/II clinical trials of its Covid-19 vaccine candidate, CoronaVac. Results from the randomised, double-blind and placebo-controlled trials showed favourable immunogenicity and safety profiles. The Phase 2 results only included antibody-based immunity, the researchers said, adding Apr 16, 2019 · Participants in the sIPV arm of the trial developed neutralizing antibodies against poliovirus types 1, 2, and 3 with seroconversion rates of 98. Totally 1440 healthy infants of 6 weeks old (42-47 days) are planned to be enrolled, and then randomized in a 1:1:1:1 ratio into four groups, i. Nov 18, 2020 · The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. Dec 10, 2020 · Here, we report safety and efficacy findings from the phase 2/3 part of a global phase 1/2/3 trial evaluating the safety, immunogenicity, and efficacy of 30 μg of BNT162b2 in preventing Covid-19 Nov 17, 2020 · Between April 16 and April 25, 2020, 185 individuals were screened and 144 participants were enrolled in the phase 1 trial, and between May 3 and May 5, 2020, 662 individuals were screened and 600 participants were enrolled in the phase 2 trial. Mar 22, 2021 · The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. 8% against type 2 Nov 20, 2020 · Chinese vaccine maker Sinovac Biotech could have the results of its experimental COVID-19 vaccine from late-stage clinical trials as soon as next month, an executive said on Friday. Preliminary results of early to mid-stage trials showed this week that it triggered a quick immune response but lower levels of Apr 18, 2013 · Data from the Phase III trial indicated that our EV71 vaccine had 95% efficacy against EV71-associated HFMD /herpangina, and 100% efficacy against EV71-associated hospitalization. Moderna: mRNA: 3: Phase 3 clinical trial results had yet to emerge as of June 2022. Weidong Yin, Chairman, President and CEO, stated, "Commencing the Phase III EV71 vaccine trial is a significant In addition, the other two vaccines, developed by National Health Research Institutes (NHRI) of Taiwan and Inviragen Pte. According to Sinovac, the preliminary Phase III data showed that its EV71 vaccine was 95. Trials from Brazil and Turkey have revealed efficacy figures of 50. 6% among those receiving a control vaccine during the fourteen months observation period. trial). Peer-reviewed Phase III results from Turkey showed an efficacy of 83. 1%). Efficacy against symptomatic infections increased to 62. U. (NASDAQ: SVA) (Sinovac or the Company), a leading provider of biopharmaceutical products in China, today announced phase III results. The study will be carried out in multiple sites in Brazil. 65% efficacy against symptomatic disease; 83. In July, Sinovac began Phase III trials in Chile with 14,000 participants for children and adolescents and expand from 6 months to 17 years old. Background • 2-dose β-propiolactone-inactivated, aluminiumhydroxide-adjuvanted COVID-19 vaccine administered on a 0/14-28-day schedule for the prevention of COVID-19 disease • Authorized by the China National Medical Feb 5, 2021 · Sinovac Biotech Ltd. BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. S. , Ltd (Inviragen), of Singapore, have also completed Phase I clinical trials. These trials indicate that inactivated COVID-19 vaccines have an efficacy rate ranging from around 50% to 90%, depending on the vaccine and dosing regimen used . Brazil Trial : 12,396 healthcare workers. Dr. The overall incidence of serious adverse events in this trial was 2. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III Aug 11, 2020 · Sinovac's Indonesia trial comes as Southeast Asia's most populous country grapples with spiking infection numbers, with over 127,000 cases recorded as of Tuesday. 13, 2012) – Chinese biopharmaceutical company Sinovac Biotech Ltd. SVA +4. Jun 30, 2021 · In this phase 3, randomized, observer-blinded, placebo-controlled trial conducted at 33 sites in the United Kingdom, we assigned adults between the ages of 18 and 84 years in a 1:1 ratio to Dec 30, 2020 · What. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the New England Journal of Medicinehas published safety and final efficacy results from the pivotal Phase 3 trial of BNT162b2, their mRNA-based COVID-19 vaccine candidate. 7% effective in preventing mild cases needing treatment. In the trial of 43,448 participants, who were 16 Apr 20, 2018 · The phase III trial is a randomized, double-blind, controlled clinical trial to evaluate the immunogenicity and safety of sIPV in 2-month-old infants. May 31, 2023 · Several inactivated COVID-19 vaccines, including those developed by Sinovac and Sinopharm in China, have successfully completed phase 3 clinical trials with positive results. Feb 1, 2024 · Sinovac Phase 3 Trial Results The Phase 3 clinical trial of the Sinovac vaccine, an inactivated virus vaccine, determined its efficacy in preventing COVID-19 disease. 1%) of 3568 in the placebo, during a median follow-up period of 43 days after the second dose of CoronaVac in the interim results of phase 3 trial in Turkey. The conclusion of this Dec 24, 2020 · November Sinovac publishes the details of its Phase 1/2 trial in a medical journal, showing a comparatively modest production of antibodies. Observers believe that the company may release interim results on the May 22, 2018 · The high immunogenicity for these serotypes were also have been reported in other phase Ⅲ clinical trials of PPV23 Citation 17, Citation 18. Sep 11, 2023 · SINOVAC’s SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023. Trials were conducted in Brazil, Turkey, Indonesia, and Chile. Adults aged 18–59 years who were seronegative and RT-PCR-negative for SARS-CoV-2 infection received two doses of CoronaVac (3 μg β-propiolactone-inactivated SARS-CoV-2 in 0·5 mL aqueous suspension with 0·45 mg/mL aluminium) or placebo (containing all the ingredients except Nov 8, 2011 · The phase II clinical results have provided the reference data for phase III clinical trial, including the vaccination schedule and dosage selection, based on which the proper dosage can be selected to enter into the phase III clinical trial. Reuters. 5% Jul 25, 2022 · Serious adverse events were reported in 11 (0. The seroconversion rate and GMT for the medium dose group was 98. The results of phase III clinical trials in Brazil, Turkey, Indonesia, and Chile indicate that CoronaVac is safe and can trigger a protective immune response against SARS-CoV-2, with efficacy or Oct 15, 2020 · Trial design. Governor João Doria added that Phase 2 trials of the potential vaccine had shown an immune response of 98% in the elderly. Only a Phase 3 trial will demonstrate if that is enough Jun 14, 2021 · News Release. 2012-06-26 Although no antibody-dependent enhancement phenomenon or vaccine-associated enhanced respiratory disease was observed in the preclinical studies in different animal models, 5,6 phase 1/2 trials, 3,4 and the current phase 3 trial with a large sample size, longer follow-up is needed to provide firm conclusions about the possibility of vaccine Mar 14, 2013 · /PRNewswire/ -- Sinovac Biotech Ltd. Methods. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are pleased to report an over 87% efficacy rate from the Phase III trial of our Varicella vaccine. 7% efficacy at preventing symptomatic infections and 83. 5%, 98. A COVID-19 vaccine developed by China’s Sinovac was shown to be 78 percent effective during its final-stage trials in Brazil Aug 4, 2021 · – ALLEGRO 2b/3 trial met primary efficacy endpoint of improving scalp hair regrowth – Pfizer Inc. (“Sinovac Beijing”) on the unblinding conference held on April 19, 2018. The purpose for the phase III clinical trial is to evaluate the efficacy of protection against HFMD Jun 30, 2021 · The combined safety results from Phase I/II showed that, among 550 subjects who received at least one dose of the vaccine candidate or placebo, the incidence of adverse reactions within 28 days Jul 8, 2021 · CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. Taking safety, immunogenicity, and production capacity into account, the 3 μg dose of CoronaVac is the suggested dose for efficacy assessment in future trials, with ongoing trials investigating on the day 0 and 14 vaccination schedule, and future phase III clinical trials investigating on the day 0 and 28 vaccination schedule. Results of Phase III trials. Through this collaboration, Instituto Butantan will sponsor Phase III clinical trials in Brazil. But for Dr. Aug 28, 2021 · Reported results from previous phase 3 clinical trials for Covid-19 vaccines from Sinopharm, Sinovac Biotech, and CanSino Biologics ranged from 51 to 79 per cent. On 5 February 2021 – a day before China approved CoronaVac for general use – Sinovac announced the vaccine’s Phase 3 results from Brazil and Turkey. Sinovac anticipates the trial to be completed in the first half of 2013. May 4, 2021 · Data on CoronaVac from clinical trials and national vaccination campaigns have also emerged, with mixed results. K. 70% efficacy against symptomatic disease requiring medical Feb 5, 2021 · Sinovac Biotech Ltd. Sinovac's CoronaVac is in large late-stage trials in Brazil, Indonesia and Turkey. November 20, 2020 at 5:21 AM Sep 9, 2020 · According to the results, the medium dose was selected to enter into phase III trial. May 9, 2023 · This is a multi-country, multi-center, open-labelled, randomized, controlled, extended phase Ⅲ clinical trial. clinical trial results show Novavax vaccine is safe and prevents COVID-19. This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac. Hum Vaccin Immunother. 3% Nov 20, 2020 · Sinovac may get Phase III trial results of COVID-19 vaccine by Dec, executive says. 0% and 42. pneumoniae serotypes in China were 19F, 19A, 23F, 14, and 6B, for which the Sinovac PPV23 induced a 2-fold increase rate at about 70%. Company. Sep 25, 2017 · Mr. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey. This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The Phase 2 results only . 26, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. Results from a Phase 3 clinical trial enrolling 29,960 adult volunteers in the United States and Mexico show that the investigational vaccine known as NVX-CoV2373 demonstrated 90. or “Sinovac R&D”), a wholly owned subsidiary of the Jul 8, 2021 · present the interim results of a double-blind, randomised, controlled trial of CoronaVac versus placebo in Turkey. The Jun 11, 2012 · In May 2012, an expert from the Center for Drug Evaluation within the State Food and Drug Administration (SFDA) completed an inspection of the three Phase III study sites in Jiangsu Province, as Jan 8, 2021 · Sinovac's COVID-19 vaccine 78% effective in phase 3 trial in Brazil. SINOVAC at Glance; Our History; Sinovac Announces Preliminary Results of Phase III Trial on sIPV. 6% in the current trial and 86. In contrast to mRNA vaccines developed by PFIZER and MODERNA, which showed efficacy rates of 95% and 94% respectively, the Sinovac vaccine displayed an efficacy rate of 50%. 2% among the EV71 candidate vaccine recipients and 2. 34 percent, but it did not provide any further trial data, making it impossible for outside Nov 20, 2020 · Chinese vaccine maker Sinovac Biotech could have the results of its experimental COVID-19 vaccine from late-stage clinical trials as soon as next month, an executive said on Friday. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine ("sIPV") developed by Sinovac Biotech Co. Sep 9, 2020 · The phase I/II clinical trial on elderly volunteers were randomized, double-blinded and placebo controlled trials with two-dose immunization scheduled at 28 day intervals. ( or “Sinovac LS”, previously known as Sinovac Research and Development Co. 4% efficacy in preventing symptomatic COVID-19 disease. CoronaVac received the approval from the National Medical Products Administration (NMPA) in April 2020 to conduct phase I to III clinical trials. The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China. 50. Jun 11, 2020 · In addition, Sinovac is constructing a commercial vaccine production plant in China that is expected to manufacture up to 100 million doses of CoronaVac annually. Key evidence to inform policy recommendations on the use of CoronaVac. or Jan 31, 2024 · In an ongoing phase 3, double-blind trial in Brazil, we randomly assigned participants to receive Butantan-DV or placebo, with stratification according to age (2 to 6 years, 7 to 17 years, and 18 Aug 11, 2020 · Vaccines used in the late-stage trials will be made using the optimised process, a Sinovac spokesman said. The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. Read full article. Jul 6, 2020 · " The phase III clinical trial approval is a demonstration that the Sinovac and Butantan partnership is an efficient collaboration to move forward offering hope to save lives worldwide," commented May 18, 2020 · Also on February 5, Sinovac announced data from a 12,396-participant, Phase III trial in Brazil and Turkey showing CoronaVac to be 100% effective in preventing death or hospitalization in patients Nov 10, 2020 · Next : A Phase III Clinical Trial of the 5-Dose Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strain Recommended news for you SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F Jun 26, 2012 · Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status . Jul 31, 2020 · AstraZeneca, which published 3 promising early trial results for its vaccine — based on a chimpanzee cold virus — the same day as CanSino, is carrying out phase III studies in the United Dec 15, 2021 · Similar protection against this variant was observed in the earlier phase 3 trial conducted in the United Kingdom 13 (vaccine efficacy, 93. (), a leading provider of vaccines in China, announced today preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Varicella vaccine against Chickenpox. 1%. , a leading provider of biopharmaceutical products in China, today announced positive preliminary results of phase I/II clinical trial for the Company’ s COVID-19 vaccine Jun 30, 2021 · The combined safety results from Phase I/II showed that, among 550 subjects who received at least one dose of the vaccine candidate or placebo, the incidence of adverse reactions within 28 days after the injection was 26% (56 / 219) in the low-dose group, 29% (63 / 217) in the medium-dose group and 24% (27 / 114) in the control group, with no Jan 13, 2012 · AsianScientist (Jan. Aug 31, 2022 · Sinovac: Inactivated: 3: Approved in China. May 27, 2021 · The Chinese drug maker Sinopharm has finally published the interim results from a phase 3 trial of its Covid-19 vaccine after more than 200 million doses have been administered worldwide. Sinovac had started its phase III trials Feb 8, 2022 · Method: We conducted a phase III, randomized, double-blind, positive-controlled trial in which 1300 healthy infants were randomly assigned to four groups in a 1:1:1:1 ratio to receive one of the three lots of the sIPV or the control IPV at 2, 3 and 4 months of age. EVIDENCE ASSESSMENT: CoronaVacCOVID-19 vaccine. The final efficacy rate was based on 41 infections, 32 of which had Apr 19, 2018 · BEIJING, April 19, 2018 -- Sinovac Biotech Ltd. 3% in the U. Jul 8, 2021 · We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey. 4 percent (95% CI: 87. Jul 14, 2020 · On July 3, 2020, the Brazilian National Regulatory Agency, Anvisa, granted approval to a phase III clinical trial sponsored by Instituto Butantan to test efficacy and safety of the inactivated COVID-19 vaccine developed by Sinovac Life Sciences Co. Phase III results from Brazil previously showed 50. 5% (95% CI, 65. Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19 Jul 19, 2022 · Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the positive results from the Company’s Phase III clinical study of a Sabin strain-based inactivated polio vaccine (sIPV) developed by Sinovac were published in the Journal of SINOVAC: Supply Vaccines to Eliminate Human Diseases. Nov 18, 2020 · Sinovac’s Phase 1 trial began in April with 144 participants, and its Phase 2 trial began in May with 600 people. Jun 11, 2020 · SINOVAC: Supply Vaccines to Eliminate Human Diseases. e. 7% and 83. The trial commenced in August 2017 with twelve hundred healthy volunteer subjects enrolled in the study. Feb 6, 2021 · “Sinovac has published a press release reporting the results of phase III trials of CoronaVac, its COVID-19 vaccine. The vaccination schedule calls for two shots at 0 and 28 days. , Ltd. By Reuters. Apr 2, 2015 · This is a randomized, multicenter, double-blind, placebo-controlled Phase III study that will evaluate efficacy and safety of a live attenuated, tetravalent, lyophilized dengue vaccine produced by Butantan Institute. Volunteers aged 18–59 years with no history of COVID-19 and with negative PCR and antibody test results for SARS-CoV-2 were enrolled at 24 centres in Turkey. Citation 11 In the phase 3 trial in Brazil Jan 7, 2021 · Sinopharm had announced that its Phase 3 trials showed that its vaccine had an efficacy rate of 79. Mar 21, 2021 · Sinovac Announces Phase 3 Trial Results. has begun the Phase III clinical trial for its proprietary inactivated EV71 vaccine against hand, foot and mouth disease (HFMD). Approximately 42% of global participants and 30% of U. 2 in elderly volunteers Dec 10, 2020 · NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the BEIJING, March 10, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ws rl vv fd lr me fb os vn ln